Proposed amendments would enable the complaints body to hear disputes arising from Australia's new ban on the use of adverse genetic test results in life insurance underwriting.
New policy addresses management liability needs unique to life sciences, biotech, and pharmaceutical firms and is specifically designed for the R&D ecosystem.
The Premier Life Science policy provides coverage across multiple lines of business to life sciences companies in Singapore, Australia, Hong Kong, and Korea.
